Abstract

Researchers at the Burnham Institute and Dana-Farber have independently identified peptides that modulate BCL-2-mediated apoptosis in strikingly opposite ways. One company, Aileron, has already been formed around the Dana-Farber findings, whereas the Burnham group is considering developing D-enantiomers or mimetics to optimize its peptide's performance.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call